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Introduction: Several single institution phase I and phase II trials of stereotactic ablative body radiotherapy (SABR)
for liver tumors have reported promising results and high local control rates of over 90%. However, there are wide
variations in dose and fractionation due to different prescription policies and treatment methods across SABR series
that have been published to date.
This study aims to assess and minimize inter-institutional variations in treatment planning using SABR for
hepatocellular carcinoma (HCC) in preparation for a prospective multi-institutional study.
Methods: Four institutions (A-D) participated in this study. Each institution was provided with data from four
cases, including planning and diagnostic CT images and clinical information, and asked to implement three plans
(a practice plan and protocol plans 1 and 2). Practice plans were established based on the current treatment
protocols at each institution. In protocol plan 1, each institution was instructed to prescribe 40 Gy in five fractions
within 95% of the planning target volume (PTV). After protocol plan 1 was evaluated, we made protocol plan 2, The
additional regulation to protocol plan 1 was that 40 Gy in five fractions was prescribed to a 70% isodose line of the
global maximum dose within the PTV. Planning methods and dose volume histograms (DVHs) including the
median PTV D50 (Dm50) and the median normal liver volume that received 20 Gy or higher (Vm20) were compared.
Results: In the practice plan, Dm50 was 48.4 Gy (range, 43.6-51.2 Gy). Vm20 was 15.9% (range, 12.2-18.9%). In
protocol plan 1, the Dm50 at institution A was higher (51.2 Gy) than the other institutions (42.0-42.2 Gy) due to
differences in dose specifications. In protocol plan 2, variations in DVHs were reduced. The Dm50 was 51.9 Gy
(range, 51.0-53.1 Gy), and the Vm20 was 12.3% (range, 10.4-13.2%). The homogeneity index was nearly equivalent at
all institutions.
Conclusions: There were notable inter-institutional differences in practice planning using SABR to treat HCC. The
range of PTV and normal liver DVH values was reduced when the dose was prescribed to an isodose line within
the PTV. In multi-institutional studies, detailed dose specifications based on collaboration are necessary.
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Hepatocellular carcinoma (HCC) primarily affects patients
with chronic liver disease. Patients with chronic hepatitis
or cirrhosis secondary to viral hepatitis B or C and
alcoholism are at the highest risk of developing HCC.
Clinical practice guidelines [1,2] recommend surgical re-
section, transplantation or percutaneous ablation to treat
solitary HCC in patients with adequate liver function.
Stereotactic ablative body radiotherapy (SABR) is an
emerging treatment modality that enables delivery of
ablative doses to tumors with acceptable toxicity. Several
single institution phase I and phase II trials of SABR for
liver tumors have reported promising results and high
local control rates of over 90% [3-6]. Additional multi-
institutional prospective studies could establish this as
an alternative treatment for patients who are ineligible
for other local treatments for solitary HCC. However,
there are wide variations in dose and fractionation due
to different prescription policies and treatment methods
across SABR series that have been published to date
[3,4,7-9].
We assessed inter-institutional variations in SABR plan-
ning to treat HCC and run a benchmark in preparation
for a multi-institutional prospective study.
Methods
Study schemes
Four institutions (A, B, C and D) participated in this
study. Anonymized data from four benchmark cases
with HCC were distributed to the participating institu-
tions, including planning computed tomography (CT)
images, pretreatment triphasic CT images and clinical
information. Planning CT images from each case are shownFigure 1 Planning computed tomography images. Outer and inner line
respectively. Case 1, hepatocellular carcinoma (23 mm) located in segment
located just below the diaphragm in S4; case 3, hepatocellular carcinoma (
and case 4, hepatocellular carcinoma (40 mm) located in S6/7.in Figure 1. The tumors were in different locations with
maximum tumor diameters of 22, 23, 25 and 40 mm.
Structure sets of the liver, gross tumor volume (GTV),
internal target volume (ITV) and planning target volume
(PTV) were also provided. The PTV of case 1, 2, 3, and 4
were 35.4, 50.5, 87.6 and 105.8 cc, respectively. Pretreat-
ment triphasic CT images were acquired at a resting
expiratory level with the patient in a vacuum pillow and
under abdominal compression. Planning CT images were
acquired in a long scan (6–8 seconds/slice) during free
breathing. GTV was contoured on pretreatment triphasic
CT and combined with planning CT. CTV was equated to
GTV. ITV was inserted on the planning CT image by
adding margins (2–6 mm) to the GTV according to respira-
tory movements measured by fluoroscopy. PTV was deter-
mined by adding 2 mm to the ITV. Normal liver was
defined as the liver minus GTV. The four patients were
informed regarding use of their clinical data for this study
and provided written informed consent.
Treatment plans
At each institution, planning CT images and structure
sets were imported into a radiotherapy treatment plan-
ning system (TPS), and study plans were created. The
beam x-ray energy was set at 6 MV. Different dose
calculation algorithms were allowed.
Routine clinical plans (practice plans) were established
according to current treatment protocols at each institu-
tion, including prescription dose, prescription point and
dose constraints. Another plan included prescribing 40
Gy in five fractions at 95% of the PTV (protocol plan 1).
After analyzing and discussing the results of protocol
plan 1, each institution was asked to implement ans indicate the planning target volume and gross tumor volume,
1 (S1) near the duodenum; case 2, hepatocellular carcinoma (25 mm)
22 mm) located in S5 near the inferior vena cava and the duodenum;
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prescribed at the 70% isodose line of the global max-
imum dose within the PTV in which 95% of the PTV
received more than 40 Gy (protocol plan 2).
Plan comparisons
Planning CT images, structure sets, plans and doses
from each institution were collected and imported to the
treatment planning system (Eclipse, version 10.0, Varian,
Palo Alto, CA). The following items were also collected
and compared: radiotherapy unit, radiotherapy TPS,
dose calculation algorithm, prescription dose, prescrip-
tion point, beam arrangement, planning CT methods,
target volume delineation methods and dose constraints.
Dose volume histograms (DVHs) of the GTV, PTV and
normal liver from each plan at each institution were
evaluated. Median D50 (Dm50), Dm90, Dm98, maximum
dose and minimum dose were acquired. Median normal
liver volume receiving 20 Gy or higher (Vm20) and
median mean normal liver dose (MLDm) were used to
evaluate the normal liver dose. For GTV and PTV, the
homogeneity index (HI) was defined as the maximumTable 1 Planning and treatment parameters
A B
TPS XiO iPlan
Calculation algorithm SuperPosition Pencil Beam
Prescription dose ChildA: 40Gy/5fr 44Gy/4fr
ChildB: 35Gy/5fr
Prescription point 70% isodose Isocenter
Beam arrangement Dynamic conformal arc Dynamic conformal a










Target definition CT Fusion of LSTCT + dynamic CT Fusion of 4 times bre
Planning CT LSTCT LSTCT
ITV GTV + 2-6mm Fusion of 4 times bre
PTV ITV + 2mm ITV + CC10mm, AP, L
Dose constraints
Liver V20(include PTV) < 20% V<16 > 700 cc
Spinal cord Dmax < 25Gy, D1cc < 20Gy Dmax < 25Gy/4fr
GI tract Dmax < 25Gy, D1cc < 20Gy D10cc < 35Gy/4fr
Kidney - V20 < 30%
Heart - -
Gallbladder - -
Abbreviations: TPS, treatment planning system; XVMC, X-ray voxel Monte Carlo algo
perigastrointestinal; RPM, The Varian® Real-time Position Management™ system; GI,
4-dimensional computed tomography; AveIP, average intensity projection; GTV, gros
CC, cranial and caudal; LRA, left, right and anterior; P, posterior; LR, left and right; APdose delivered to 2% of the target volume (D2) minus
D98 divided by D50. Dose conformity was evaluated in
terms of conformation number (CN) [10], quantified as:
VT;pi=VT
   VT;pi=Vpi
 
;
where: VT, pi = volume within the PTV receiving a dose ≥
the prescription dose, Vpi = volume receiving a dose ≥
the prescription dose, VT = PTV. We had defined met-
rics for planning evaluation before protocol plan 1,
therefore we used same metrics to evaluate protocol
plan 1 and 2.
Results
Current planning and treatment protocols at participating
institutions are shown in Table 1. Remarkable variations
between each institution were observed. Institutions A
and B used non-coplanar and coplanar dynamic con-
formal arc beams, respectively. In contrast, institutions C
and D used non-coplanar static beams. At institution A,
the prescribed dose was to the 70% isodose line within theC D
iPlan Pinnacle
XVMC CCCS




Non-coplanar, 6–8 beams Non-coplanar, 6-8 arcs
ing Confined free-breathing Gated by Abches® or RPM
Under abdominal compression
athing CT Fusion of 4DCT + breath-hold CT Breath-hold CT
AveIP from 4DCT Breath-hold CT
athing CT Directly visualized by LSTCT ITV = GTV
R8mm ITV + 5mm ITV + CC8mm, AP, LR5mm
V20 < 25% V<15 > 700 cc V20≦25%
Dmax < 25Gy/4fr Dmax < 25Gy/4fr
D1cc < 40Gy/4fr, D10cc < 35Gy/4fr D1cc < 30Gy/4fr, D10cc
< 24Gy/4fr
V20 < 30% D1/3 < 20Gy/4fr
- D1/3 < 28Gy/4fr
- D1/3 < 40Gy/4fr
rithm; CCCS, collapsed cone convolution superposition; periGI,
gastrointestinal; LSTCT, long scan time computed tomography; 4DCT,
s tumor volume; PTV, planning target volume; ITV, internal target volume;
, anterior and posterior.
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to an isocenter.
Practice plan
GTV, PTV and normal liver DVHs for case 4 are shown
in Figure 2a-c. The shoulder of the PTV DVH had a
lower gradient and higher maximum dose at institution
A compared to the other institutions. There was signifi-
cant variation among DVHs in target volume, although
low variation was observed in the normal liver. Dm95
and Dm50 of PTV of the four cases were 43.5 Gy (range,
41.1-46.5 Gy) and 48.4 Gy (range, 43.6-51.2 Gy), respec-
tively. Vm20 and MLDm were 15.9% (range, 12.2-18.9%)
and 10.8% (range, 8.8-12.5%), respectively. Median HI
was higher at institution A (Table 2, Figure 3).
Protocol plan 1
In protocol plan 1 (Table 2, Figure 2d-f), all of the institu-
tions used a D95 of 40 Gy in all cases. Except for GTV
and PTV DVHs at institution A, there was little variation
in GTV, PTV and normal liver DVHs at each institution.
PTV Dm50 at institution A was higher than at the other
institutions. Vm20 and MLDm were 13.9% (range, 11.7-
17.5%) and 9.8 Gy (range, 8.8-11.4 Gy), respectively. HI
was higher at institution A (Table 2, Figure 3). CN atFigure 2 Dose volume histograms of case 4. (a) GTV, (b) PTV and (c) no
protocol plan 1; and (g) GTV, (h) PTV and (i) normal liver in protocol plan 2institution C was relatively lower than at the other three
institutions.
Protocol plan 2
In protocol plan 2 (Table 2, Figure 2g-i), all of the insti-
tutions complied with the dose constraints. Regarding
variation among GTV and PTV DVHs in protocol plan
2, the range of DVH values was reduced compared with
protocol plan 1. Although the DVH shape was similar to
the shape observed in the practice plan and protocol
plan 1, Vm20 and MLDm were lower than the other two
plans. Dose distribution at each institution is shown in
Figure 4. Median HI and CN values were nearly equiva-
lent at all institutions (Table 2, Figure 3).
Discussion
SABR is expected to be a treatment option indicated for
HCC patients who are ineligible for surgery or radio-
frequency ablation. However, various dose prescription
and treatment planning strategies are currently used by
different groups [3,4,7-9] and an optimal dose has not
been determined.
For trials involving advanced radiation therapy tech-
niques, the minimum acceptable degree of protocol compli-
ance must be described to mitigate unacceptable variationrmal liver in the practice plan; (d) GTV, (e) PTV and (f) normal liver in
.
Table 2 Dose-volumetric data of target volumes
A B C D
Median (Min - Max)
Practice-plan
GTV Dm50 (Gy) 55.2(52.6-55.8) 44.1(43.3-44.2) 49.0(44.2-55.5) 47.9 (46.6 - 48.5)
Dm95 (Gy) 53.1(48.8-54.2) 42.7(41.3-43.7) 47.6(44.2-54.3) 47.2 (46.6 - 47.8)
Dm98 (Gy) 52.3(47.8-53.8) 42.6(41.1-43.6) 47.5(43.9-54.0) 47.2 (46.4 - 47.7)
Min (Gy) 50.0(49.3-53.1) 42.2(40.9-43.3) 46.8(43.1-53.4) 46.3 (39.6 - 47.0)
Max (Gy) 57.1(57.1-57.1) 45.1(44.6-47.8) 51.8(50.9-57.2) 49.0 (41.2 - 49.7)
PTV Dm50 (Gy) 51.2(49.5-52.1) 43.6(42.7-44.0) 49.0(46.4-55.4) 47.7 (47.5 - 47.8)
Dm95 (Gy) 41.2(41.0-41.5) 41.1(40.7-41.9) 46.5(43.2-53.4) 45.7 (45.5 - 46.5)
Dm98 (Gy) 39.0(38.4-39.8) 40.5(39.8-41.3) 45.9(42.5-52.9) 45.3 (44.7 - 46.1)
Min (Gy) 32.5(27.5-34.0) 37.1(35.4-37.3) 40.5(37.7-50.7) 43.7 (41.9 - 45.0)
Max (Gy) 57.1(57.1-57.1) 45.2(44.7-48.9) 40.5(51.7-57.7) 43.7 (48.7 - 49.9)
HI 0.34(0.33-0.36) 0.10(0.08-0.19) 0.12(0.08-0.18) 0.08 (0.06 - 0.09)
Vm20 (normal liver) (%) 13.2(6.7-14.1) 12.2(6.5-14.9) 18.9(13.7-22.3) 18.5 (10.1 - 23.2)
MLDm (Gy) 9.3(7.1-11.2) 8.8(7.1-10.4) 12.5(10.9-13.2) 12.2 (8.7 - 14.0)
Protocol-plan1
GTV Dm50 (Gy) 55.2(52.6-55.8) 42.7(42.0-43.1) 42.0(41.6-43.1) 42.4 (42.2 - 42.7)
Dm95 (Gy) 53.1(48.8-54.2) 41.6(40.2-42.0) 40.8(40.6-41.2) 44.5 (41.2 - 42.7)
Dm98 (Gy) 52.3(47.8-53.8) 41.5(40.0-42.0) 40.6(40.4-41.0) 41.4 (41.1 - 42.1)
Min (Gy) 50.0(49.0-53.0) 41.0(39.7-42.0) 39.9(39.6-40.4) 41.0 (40.7 - 42.0)
Max (Gy) 57.1(57.1-57.1) 57.1(43.1-46.7) 50.6(43.1-47.6) 45.4 (43.1 - 44.5)
PTV Dm50 (Gy) 51.2(49.5-52.1) 42.2(41.8-43.1) 42.0(41.6-43.1) 42.0 (41.6 - 42.2)
Dm95 (Gy) 41.2(41.0-41.5) 40.0(40.0-40.1) 40.1(40.1-40.2) 40.0 (40.0 - 40.2)
Dm98 (Gy) 39.0(38.4-39.8) 39.5(39.4-39.6) 39.7(39.7-39.8) 39.6 (39.2 - 39.8)
Min (Gy) 32.5(27.5-34.0) 36.4(34.1-37.5) 38.9(38.6-39.1) 37.3 (36.6 - 40.7)
Max (Gy) 57.1(57.1-57.1) 44.2(43.3-48.2) 45.1(43.3-48.8) 43.5 (43.4 - 44.5)
HI 0.34(0.33-0.36) 0.10(0.09-0.19) 0.11(0.07-0.17) 0.09 (0.07 - 0.10)
CN 0.85(0.81-0.91) 0.89(0.80-0.90) 0.63(0.59-0.68) 0.85(0.75 - 0.86)
Vm20 (normal liver) (%) 13.2(6.7-14.1) 11.7(6.2-14.6) 17.5(10.0-19.1) 14.6(8.8 - 15.5)
MLDm (Gy) 9.3(7.1-11.2) 8.8(6.9-9.9) 11.4(8.6-12.3) 10.2 (7.6 - 10.4)
Protocol-plan2
GTV Dm50 (Gy) 55.2(52.6-55.8) 55.3(53.2-56.3) 53.6(51.6-55.0) 56.2 (55.9 - 56.6)
Dm95 (Gy) 53.1(48.8-54.2) 53.2(50.7-55.6) 50.6(48.6-53.3) 52.6 (51.2 - 54.7)
Dm98 (Gy) 52.3(47.8-53.8) 52.2(47.4-55.3) 50.1(48.0-52.8) 50.3 (47.4 - 53.0)
Min (Gy) 50.0(49.3-53.1) 51.5(45.0-54.7) 49.7(47.1-53.8) 47.0 (42.6 - 50.5)
Max (Gy) 57.1(57.1-57.1) 57.1(57.1-57.1) 57.1(57.1-57.1) 57.1 (57.1 - 57.1)
PTV Dm50 (Gy) 51.2(49.5-52.1) 52.5(51.5-54.0) 51.0(49.9-52.3) 53.1 (50.8 - 53.8)
Dm95 (Gy) 41.2(41.0-41.5) 40.0(40.0-40.2) 40.1(40.0-40.3) 40.6 (40.4 - 41.3)
Dm98 (Gy) 39.0(38.4-39.8) 37.1(36.7-37.7) 37.8(37.4-38.2) 38.5 (36.3 - 38.9)
Min (Gy) 32.5(27.5-34.0) 21.5(18.5-23.6) 26.9(24.9-28.8) 29.5 (25.8 - 32.4)
Max (Gy) 57.1(57.1-57.1) 57.1(57.1-57.1) 57.1(57.1-57.1) 57.1 (57.1 -57.1)
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Table 2 Dose-volumetric data of target volumes (Continued)
HI 0.34(0.33-0.36) 0.37(0.36-0.38) 0.36(0.35-0.39) 0.35 (0.35 -0.39)
CN 0.85(0.81-0.91) 0.90(0.88-0.91) 0.89(0.87-0.91) 0.89 (0.85 -0.89)
Vm20 (normal liver) (%) 13.2(6.7-14.1) 11.5(6.3-14.0) 10.4(6.3-13.7) 13.0 (6.8 -13.7)
MLDm (Gy) 9.3(7.1-11.2) 8.3(7.0-9.9) 8.9(8.0-10.9) 9.5 (6.4 - 10.2)
Abbreviations: GTV, gross tumor volume; PTV, planning target volume; HI, homogeneity index; CN, conformation number; MLD, mean liver dose.
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ences in planning and treatment protocols at several insti-
tutions (Table 1). In conducting a clinical trial of SABR,
treatment planning can vary based on multiple factors,
such as planning CT, target volume delineation, beam
arrangement, dose calculation algorithms and prescription
point [12]. It is difficult to unify the method to acquire
planning CT because treatment modalities vary among
institutions. In regard to measures to account for respira-
tory movement, it is important to set up some criteria
with acceptable range in preparing for a protocol. Calcula-
tion algorithms have influence on dose distribution when
some beams pass through materials with air density,Figure 3 Homogeneity index (HI) and conformation number (CN)
at institutions A-D. Median (a) HI and (b) CN at institutions A-D.therefore newer generation calculation algorithms such as
superposition or comparable algorithm may be preferable.
Variations in target delineation have been reported by
several investigators [13,14]. Delineation of HCC can also
be affected by scanning protocol of triphasic CT, with or
without use of MRI. In this study, identical target volumes
were intentionally delineated prior to data distribution to
eliminate variation and enable direct comparison of DVH
parameters used in different planning methods.
In the practice plan, PTV dose distribution varied
among institutions due to differences in prescription
dose and prescription point. A uniform prescription
dose of 40 Gy in five fractions administered as D95 were
required in protocol plan 1. As a result, there was a
significant gap between institution A and the other three
institutions (Figure 2d-f ) due to different prescription
methods because institution A prescribed at the 70%
isodose level relative to the global maximum dose, while
the other three institutions prescribed at the isocenter.
There are two different concepts regarding dose within
the target in SABR. One maintains dose homogeneity
within the target, which is generally prescribed at the
isocenter. The concept has been widely utilized in Japan.
In the other concept, dose is prescribed at the PTV
margin and does not maintain dose homogeneity [15].
In the latter concept, there is another variation in
prescription method which provides more flexibility and
is more treatment planning system and technique inde-
pendent. In a randomized phase III trial of Radiosurgery
Or Surgery for operable Early stage (stage 1A) non-small
cell Lung cancer (ROSEL) study, the dose prescription
was based on D95 of the PTV receiving at least the
nominal fraction dose, and D99 of the PTV receiving a
minimum of 90% of the fraction dose. The dose maxi-
mum within the PTV should preferably be between
110% and 140% of the prescribed dose. The location of
the treatment plan normalization point can be left to the
institutions preference [16].
In conventional radiotherapy, International Commission
on Radiation Units and Measurements (ICRU) Report 50
[17] recommends a uniform dose to the target volume
within −5% to +7% of the prescribed dose with a radiation
dose at the reference point, which is generally the
isocenter. In contrast, dose heterogeneity within the target
is acceptable in SABR for targets that do not involve func-
tional normal tissue, as outlined in best practice guidelines
Figure 4 Dose distribution for case 4 in protocol plan 2.
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(AAPM) Task Group 101 [18]. By ignoring dose homo-
geneity within the PTV, tight conformity with steep and
isotropic dose fall-off and high dose delivery to the target
volume can be achieved in addition to a simultaneous
reduction in the normal tissue dose [19]. In this study,
institution A prescribed the dose at a 70% isodose line.
Accordingly, protocol plan 2 required dosing to the 70%
isodose line of the global maximum dose within 95% of
the PTV. As a result, GTV and PTV doses were increased
in protocol plan 2, while the normal liver dose decreased
compared with protocol plan 1.
Improvements in DVH were primarily attributed to
prescribing the dose at the 70% isodose line. Widder
et al. [20] reported that dose prescription in SABR for
lung cancer at isodose levels between 50% and 70% of
the dose at the isocenter resulted in a lower dose to
surrounding tissues and lungs compared with an 80%
isodose level. Although there are no reports on optimal
isodose levels for SABR to treat HCC, prescription to
the 70% isodose level rather than an isocenter improved
dose distribution in the current study.
Differences in DVH parameters between institutions,
particularly in the V20 and MLD in the practice plan
and protocol plan 1, were grouped according to static
and dynamic beam arrangements. Institutions A and B,
which used a dynamic conformal arc, had lower V20
and MLD values than institutions C and D, which used
non-coplanar static beams. Although a greater number
of beams generally results in better conformity and dose
distribution gradients, six to eight non-coplanar static
beams sufficiently fulfilled the planning requirement in
protocol plan 2. Prescription at the 70% isodose line
successfully reduced the dose to surrounding normal
tissues regardless of different beam arrangements.In addition to improving planning quality, the current
study shared treatment strategies at various institutions.
After data collection, researchers from the institutions
discussed their treatment planning policies and compared
study results. With respect to dose distribution at each
institution (Figure 4), institution C selected beam direc-
tions that increased non-irradiated normal liver volume as
much as possible, while institutions A and B were not as
concerned about low doses to the normal liver. Institution
D indicated that avoiding as much of the gastrointestinal
tract as possible rather than dose reduction in the normal
liver was important. Multi-leaf collimator margin size also
varied among institutions, from uniform margins around
the PTV (generally 5 to 10 mm) to variable margins in
three-dimensional directions, due to different dose pre-
scription policies. This information, which was discussed
in person, can favorably influence researchers toward
improved treatment planning. This study uncovered
possible variations in SABR planning among participating
institutions and would help to prepare for a comprehensive
protocol as well as to define credentialing and evaluation
criteria beforehand. In multi-center clinical trials, main-
taining protocol treatment quality by minimizing these
variations is a challenge. Therefore, this type of study prior
to establishing a protocol is in agreement with the goals of
quality assurance (QA) programs that attempt to minimize
variations. According to a meta-analysis and a systematic
review, radiation therapy protocol deviations are asso-
ciated with increased risk of treatment failure and overall
mortality [21,22]. Well-organized QA programs will result
in improved reliability of clinical trials and quality of
practice [23].
As limitations, the current study only compared treat-
ment planning methods directly related to SABR and did
not consider other factors that could affect treatment,
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of at-risk targets and organs, patient fixation and respira-
tory gating. Calculation algorithms were not a key focus,
which could influence dose distribution under specific
conditions. The impact of variations in calculation
algorithms based on dose distribution should be further
evaluated.
Conclusion
In planning SABR to treat HCC, there were notable
inter-institutional differences. When the dose was
prescribed to an isodose line fitted to the PTV surface,
prescription requirements were fulfilled and differences
in DVH between institutions decreased significantly. In
multi-institutional studies, detailed dose specifications
based on collaboration are necessary. A thoroughly des-
cribed protocol with a radiotherapy QA program will
lead to high-quality treatment and reliable results.
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